Stock VRTX VERTEX PHARMACEUTICALS INCORPORATED
Add to a list
To use this feature you must be a member
Log inSign up

Vertex Pharmaceuticals Incorporated Stock

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
483 USD -0.51% Intraday chart for Vertex Pharmaceuticals Incorporated +6.08% +18.72%
Jun. 07 Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Jun. 05 Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT

Financials (USD)

Sales 2024 * 10.75B Sales 2025 * 11.67B Capitalization 125B
Net income 2024 * 3.96B Net income 2025 * 4.46B EV / Sales 2024 * 10.4 x
Net cash position 2024 * 13.97B Net cash position 2025 * 18.59B EV / Sales 2025 * 9.14 x
P/E ratio 2024 *
32.3 x
P/E ratio 2025 *
28.6 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.9%
More Fundamentals * Assessed data

Chart Vertex Pharmaceuticals Incorporated

Dynamic Chart

Latest news about Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
Vertex Pharmaceuticals Incorporated completed the acquisition of Alpine Immune Sciences, Inc. from a group of shareholders. CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
Declaration of Voting Results by Vertex Pharmaceuticals Incorporated CI
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director CI
More news

Latest transcript on Vertex Pharmaceuticals Incorporated

Logo Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
More transcripts

Analyst Recommendations on Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480 MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing MT
More recommendations

Press releases Vertex Pharmaceuticals Incorporated

Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® BU
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer AQ
Vertex Pharmaceuticals Incorporated : 2024 VRTX William Blair Growth Stock Conference Presentation vFinal PU
Vertex to Participate in Upcoming June Investor Conferences BU
Jennifer Schneider Elected to Vertex Board of Directors BU
More press releases

News in other languages on Vertex Pharmaceuticals Incorporated

ETF de la semana: Las energías limpias vuelven a despegar
ETF de la semana: Las materias primas siguen teniendo potencial
Compañías que se deben tener muy en cuenta por técnico este viernes en Wall Street
ETF de la semana: Los “utilities” desempeñan un papel en la aparición del AII
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street
More news

Quotes and Performance

1 day-0.51%
1 week+6.08%
Current month+6.08%
1 month+17.75%
3 months+17.66%
6 months+36.47%
Current year+18.72%
More quotes

Highs and lows

1 week
453.73
Extreme 453.73
486.43
1 month
412.12
Extreme 412.12
486.43
Current year
391.01
Extreme 391.01
486.43
1 year
323.02
Extreme 323.02
486.43
3 years
176.36
Extreme 176.36
486.43
5 years
165.23
Extreme 165.23
486.43
10 years
63.68
Extreme 63.68
486.43
More quotes

Managers and Directors - Vertex Pharmaceuticals Incorporated

Managers TitleAgeSince
Reshma Kewalramani CEO
 Chief Executive Officer 51 17-01-31
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Charles Wagner DFI
 Director of Finance/CFO 56 19-04-09
Members of the board TitleAgeSince
Alan Garber BRD
 Director/Board Member 68 17-06-07
Jeffrey Leiden CHM
 Chairman 68 09-07-07
Bruce Sachs BRD
 Director/Board Member 64 97-12-31
More insiders

ETFs positioned on Vertex Pharmaceuticals Incorporated

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
7.67% 0 M€ 0.00% -
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
7.08% 0 M€ 0.00% -
More ETFs positioned on Vertex Pharmaceuticals Incorporated

Quotes

Date Price Change Volume
24-06-07 483 -0.51% 940,328
24-06-06 485.5 +0.52% 1,263,810
24-06-05 483 +1.70% 1,196,706
24-06-04 475 +1.01% 1,112,438
24-06-03 470.2 +3.26% 1,971,176

Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT

More quotes

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
Biotechnology & Medical Research
Calendar
2024-06-11 - Goldman Sachs Global Healthcare Conference
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5 USD
Average target price
463.5 USD
Spread / Average Target
-4.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+18.72% 125B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+14.19% 108B
BIONTECH SE Stock BioNTech SE
-4.93% 24.57B
ARGENX SE Stock argenx SE
+3.23% 22.82B
GENMAB A/S Stock Genmab A/S
-10.44% 18.19B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.74% 16.54B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.31% 16.5B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.44% 13.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.89% 11.1B
INSMED INCORPORATED Stock Insmed Incorporated
+83.45% 9.22B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VRTX Stock